Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.50 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.47 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | PLK4 | O00444 | 7/20 | 0.42 |
| ▸ | AURKB | Q96GD4 | 4/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | FLT3 | P36888 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 2/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2573765 | 0.80 | GSK3B (0.59) | GSK3BPDK2PDK4LMNAPLK4 | |
| SCHEMBL30548926 | 0.80 | GSK3B (0.59) | GSK3BPDK2PDK4LMNAPLK4 | |
| SCHEMBL19216470 | 0.80 | GSK3B (0.59) | GSK3BPDK2PDK4LMNAPLK4 | |
| SCHEMBL4778699 | 0.76 | GSK3B (0.55) | GSK3BPDK2PDK4LMNAPLK4 | |
| SCHEMBL2555060 | 0.74 | GSK3B (0.50) | GSK3BPDK2PDK4LMNAPLK4 | |
| SCHEMBL20371453 | 0.74 | GSK3B (0.50) | GSK3BPDK2PDK4LMNAPLK4 | |
| SCHEMBL14555908 | 0.74 | GSK3B (0.50) | GSK3BPDK2PDK4LMNAPLK4 | |
| SCHEMBL31435686 | 0.72 | GSK3B (0.51) | GSK3BPDK2PDK4LMNAPLK4 | |
| SCHEMBL28459489 | 0.71 | GSK3B (0.50) | GSK3BPDK2PDK4LMNAPLK4 | |
| SCHEMBL14487926 | 0.71 | GSK3B (0.50) | GSK3BPDK2PDK4LMNAPLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230012449-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. | 2023-01-12 | — | — | US | disclosed |
| US-11034668-B2 | Compounds for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2021-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11034668-B2 | Compounds for the treatment of HIV | CCR5, NPC1, FURIN | GSK3B 1733/4885PDK2 3460/4885PDK4 2940/4885 |
| US-20230012449-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | CCR5, NPC1, FURIN | GSK3B 1733/4885PDK2 3460/4885PDK4 2940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.